1 / 19

Regulatory Aspects of PK/PD – (modelling)

Regulatory Aspects of PK/PD – (modelling). Karolina Törneke Senior expert, member of the CVMP. Part 1A-C Administrative data and product information. Part 2 Pharmaceutical documentation. PK/PD!. Part 3A-B Pharmaco/toxicological and residue documentation.

maryfturner
Download Presentation

Regulatory Aspects of PK/PD – (modelling)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Regulatory Aspects of PK/PD – (modelling) Karolina Törneke Senior expert, member of the CVMP

  2. Part 1A-C Administrative data and product information Part 2 Pharmaceutical documentation PK/PD! Part 3A-B Pharmaco/toxicological and residue documentation Part 4.1 Clinical pharmacology and toxicology Part 4.2 Clinical trials

  3. Why use PK/PD (modelling)? • It increases the amount of information available • It reduces the risk for ”PK-bias” • It enables species comparison

  4. Even if the guidelines don’t talk about PK/PD as mandatory, integration of PK and PD data could be very informative and helpful • Collect PK data in experimental studies • Discuss PK and PD data in an integrated way • Use any model that could be justified dependent on the size and quality of the dataset • If no model fit – present the data anyway!

  5. Safety assessment – ”Antibact” 50 mg/kg: all experienced serious adverse reactions. 30 mg/kg: 4/5 20 mg/kg: 1/8 0-15 mg/kg: zero events Can 5-20 mg/kg be regarded as safe?

  6. Use all available data! The ”Painkill” example How to find the dose for a new species when several species are approved already with different doses?

  7. Painkill is approved for several species… • But pharmacokinetics might differ between species, e.g. differences in total body clearance and protein binding level might be prominent. • And pharmacodynamics might differ, e.g. potency or potency ratio for COX. • There might also be differences in disease pattern So before Painkill can be approved for a new species new clinical documentation on dose finding must be presented. Then PK/PD might be a valuable shortcut.

  8. PD data for Painkill were never related to PK • TXB2 concentrations measured at several time points. Results: Sex differences were recorded (lower TxB2 concentrations in females). The effect peaked at 1 h with 70 % inhibition of baseline values. At 24 h the inhibition was 40 %. • Plasma concentrations of painkill measured at the same time points. Results: AUC was larger in females than in males. There was a pronounced feed interaction recorded.

  9. Clearance for painkill: Sp 1: 1 (standardized unit/kg bw) Sp 2: 5 The dose differed accordingly and the systemic exposure was similar! New species: 5

  10. Bridging to special patient groups Knowledge about the PK/PD relationships for efficacy and safety is important for the development of appropriate dosing recommendations. The pharmacodynamics could be altered in renal impairment, which could lead to altered PK/PD relationships. (EU NfG Renal impairment studies (2004))

  11. Pharmacogenomics!

  12. What is important from a regulatory point of view? The best and most advanced of all study designs might give results that are useless for assessors! Why?

  13. The regulator’s golden questions • Is the benefit/risk positive? • Is adequate and sufficient information presented in the SPC? If both those questions could be answered and the answer is “yes” to both then the rest is “nice to know”!

  14. Zeal to be a front runner? Regulatory scientist Academicscientist Industrial scientist

  15. Appropriate objectives? • The objectives should be predefined. • The PD endpoint should be predictivefor a relevant clinical effect. • Relevant subjects should be included. • The number of included subjects should be adequate. • An appropriate dose span should be covered when PK/PD modelling is used in dose finding.

  16. One slide on antimicrobials… • PK/PD-modelling could give valuable information – if clinically relevant data is collected: • The endpoints should be relevant for the suggested indication including choice of bacterial species. • A “dose limiting strain” should be used (i.e. a strain with a MIC similar to the clinical breakpoint).

  17. Study report possible to assess? • The selected model should be justified. • Individual data including CI% for final parameters should be presented. • Goodness of fit data should be given including plots. • Conclusions should not be extrapolated. • The clinical relevance of the results should be discussed when surrogate markers are used.

  18. Conclusions • A PK/PD approach is of great value (with or without computer models) • Results could be pivotal or “nice to know” • The objectives should be predefined • The predictive value of the selected endpoints should be justified • The quality of the presentation is important • Sufficient knowledge is a prerequisite for everything else…

More Related